Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer.
Hatanaka
Kazuteru
K
Genetics Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Suzuki
Koichi
K
Miura
Yoshiaki
Y
Yoshida
Kimiko
K
Ohnami
Shumpei
S
Kitade
Yukio
Y
Yoshida
Teruhiko
T
Aoki
Kazunori
K
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D017304:Annexin A5 / Q000494:pharmacology; D015153:Blotting, Western; D016923:Cell Death; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D004305:Dose-Response Relationship, Drug; D004722:Endoribonucleases / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D018014:Gene Transfer Techniques; D011905:Genes, ras; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D020287:In Situ Nick-End Labeling; D016898:Interferon-alpha / Q000235:genetics*; D051379:Mice; D009368:Neoplasm Transplantation; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000628:therapy*; D012313:RNA / Q000378:metabolism; D012330:RNA, Double-Stranded / Q000235:genetics; D012335:RNA, Ribosomal / Q000235:genetics; D013997:Time Factors
D017304:Annexin A5; D004791:Enzyme Inhibitors; D016898:Interferon-alpha; D016376:Oligonucleotides, Antisense; D012330:RNA, Double-Stranded; D012335:RNA, Ribosomal; D012313:RNA; D004722:Endoribonucleases; C031956:2-5A-dependent ribonuclease